Childhood absence epilepsy (CAE), also known as pyknolepsy, is an idiopathic generalized epilepsy which occurs in otherwise normal children. The age of onset is between 4–10 years with peak age between 5–7 years. Children have absence seizures which although brief (~4–20 seconds), they occur frequently, sometimes in the hundreds per day. The absence seizures of CAE involve abrupt and severe impairment of consciousness. Mild automatisms are frequent, but major motor involvement early in the course excludes this diagnosis. The EEG demonstrates characteristic "typical 3Hz spike-wave" discharges. Prognosis is excellent in well-defined cases of CAE with most patients "growing out" of their epilepsy.
This report contains market size and forecasts of Childhood Absence Epilepsy Treatment in Global, including the following market information:
Global Childhood Absence Epilepsy Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Childhood Absence Epilepsy Treatment market was valued at 149.3 million in 2021 and is projected to reach US$ 183.2 million by 2028, at a CAGR of 3.0% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Ethosuximide Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Childhood Absence Epilepsy Treatment include Pfizer, GlaxoSmithKline, Cavion Inc, AbbVie, Teva Pharmaceutical and Insys Therapeutics, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Childhood Absence Epilepsy Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Childhood Absence Epilepsy Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Childhood Absence Epilepsy Treatment Market Segment Percentages, by Type, 2021 (%)
Ethosuximide
Valproate
Lamotrigine
CX-8998
Cannabidiol Oral Solution
Global Childhood Absence Epilepsy Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Childhood Absence Epilepsy Treatment Market Segment Percentages, by Application, 2021 (%)
Typical Absence Seizures
Atypical Absence Seizures
Global Childhood Absence Epilepsy Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Childhood Absence Epilepsy Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Childhood Absence Epilepsy Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Childhood Absence Epilepsy Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
GlaxoSmithKline
Cavion Inc
AbbVie
Teva Pharmaceutical
Insys Therapeutics